NEU neuren pharmaceuticals limited

ACAD made a “strategic investment” in NEU as part of the July...

  1. 6,307 Posts.
    lightbulb Created with Sketch. 22448
    ACAD made a “strategic investment” in NEU as part of the July 2018 US licence agreement.
    They acquired 1,330,000 share for A$4m, which was equivalent to ~ US$3m at the time.

    The last sighting of ACAD’s investment in NEU was at 30/06/23. The reported value at that time was US$10,781,000.

    From ACAD accounts, it appears that the company sold all of its holdings in NEU during Q3 last year.

    NEU stock price at 30/06/23 was A$12.25. The price jumped to $14.20 by 21/07/23, following the signing of the global licence between Acadia and Neuren. The stock price then tracked down to A$10.47 on 22/09/23, a 26% decline over that two month period.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.20
Change
0.890(6.69%)
Mkt cap ! $1.761B
Open High Low Value Volume
$13.50 $14.26 $12.96 $9.111M 655.8K

Buyers (Bids)

No. Vol. Price($)
1 2000 $14.17
 

Sellers (Offers)

Price($) Vol. No.
$14.23 3278 1
View Market Depth
Last trade - 16.15pm 27/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.